Literature DB >> 14617652

Quinolone resistance due to reduced target enzyme expression.

Dilek Ince1, David C Hooper.   

Abstract

We report for the first time low-level quinolone resistance mediated by decreased expression of topoisomerase IV in Staphylococcus aureus. A single-step mutant of wild-type S. aureus strain ISP794, P18 selected by using twice the MIC of premafloxacin, had four- and four- to eightfold greater MICs of premafloxacin and ciprofloxacin, respectively, than the wild type. Sequencing of parEC and gyrBA with their promoter regions revealed a point mutation (G-->A) 13 bp upstream of the start codon of parE. Genetic linkage studies showed that there was a high level of correlation between the mutation and the resistance phenotype, and allelic exchange confirmed the contribution of the mutation to resistance. Decreased expression of ParE and decreased steady-state levels of parEC transcripts in P18 and in resistant allelic exchange mutants were observed. The steady-state levels of gyrBA and topB transcripts were increased in P18 but not in two resistant allelic exchange mutants, and sequencing upstream of either gene did not reveal a difference between ISP794 and P18. The steady-state levels of topA transcripts were similar in the various strains. Growth competition experiments performed at 30, 37, and 41 degrees C with a susceptible allelic exchange strain and a resistant allelic exchange strain suggested that loss of fitness was associated with reduced levels of ParE at 41 degrees C. However, P18 had a growth advantage over ISP794 at all temperatures, suggesting that a compensatory mechanism was associated with the increased levels of gyrBA and topB transcripts. Thus, reduced levels of ParE appear to be compatible with cell survival, although there may be a fitness cost during rapid cell multiplication, which might be overcome by compensatory mechanisms without reversion of the resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617652      PMCID: PMC262703          DOI: 10.1128/JB.185.23.6883-6892.2003

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  53 in total

1.  Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance.

Authors:  J Björkman; I Nagaev; O G Berg; D Hughes; D I Andersson
Journal:  Science       Date:  2000-02-25       Impact factor: 47.728

2.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication.

Authors:  D E Adams; E M Shekhtman; E L Zechiedrich; M B Schmid; N R Cozzarelli
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

4.  Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli.

Authors:  E L Zechiedrich; N R Cozzarelli
Journal:  Genes Dev       Date:  1995-11-15       Impact factor: 11.361

5.  The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage.

Authors:  B N Kreiswirth; S Löfdahl; M J Betley; M O'Reilly; P M Schlievert; M S Bergdoll; R P Novick
Journal:  Nature       Date:  1983 Oct 20-26       Impact factor: 49.962

6.  Regulation of the genes for E. coli DNA gyrase: homeostatic control of DNA supercoiling.

Authors:  R Menzel; M Gellert
Journal:  Cell       Date:  1983-08       Impact factor: 41.582

7.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

8.  A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Authors:  M Trucksis; J S Wolfson; D C Hooper
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

Review 9.  Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.

Authors:  A K Larsen; A Skladanowski
Journal:  Biochim Biophys Acta       Date:  1998-10-01

10.  Regulation of the Escherichia coli DNA topoisomerase I gene by DNA supercoiling.

Authors:  Y C Tse-Dinh
Journal:  Nucleic Acids Res       Date:  1985-07-11       Impact factor: 16.971

View more
  21 in total

1.  Staphylococcus aureus TargetArray: comprehensive differential essential gene expression as a mechanistic tool to profile antibacterials.

Authors:  H Howard Xu; John D Trawick; Robert J Haselbeck; R Allyn Forsyth; Robert T Yamamoto; Rich Archer; Joe Patterson; Molly Allen; Jamie M Froelich; Ian Taylor; Danny Nakaji; Randy Maile; G C Kedar; Marshall Pilcher; Vickie Brown-Driver; Melissa McCarthy; Amy Files; David Robbins; Paula King; Susan Sillaots; Cheryl Malone; Carlos S Zamudio; Terry Roemer; Liangsu Wang; Philip J Youngman; Daniel Wall
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

2.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase.

Authors:  John H Tran; George A Jacoby; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.

Authors:  Jacob Strahilevitz; Ari Robicsek; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.

Authors:  Jacob Strahilevitz; Que Chi Truong-Bolduc; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 6.  Antibiotic resistance and its cost: is it possible to reverse resistance?

Authors:  Dan I Andersson; Diarmaid Hughes
Journal:  Nat Rev Microbiol       Date:  2010-03-08       Impact factor: 60.633

Review 7.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

8.  High-frequency transposition for determining antibacterial mode of action.

Authors:  Hao Wang; David Claveau; John P Vaillancourt; Terry Roemer; Timothy C Meredith
Journal:  Nat Chem Biol       Date:  2011-09-04       Impact factor: 15.040

9.  Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition.

Authors:  Peter A Smith; Floyd E Romesberg
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

10.  A role for topoisomerase III in Escherichia coli chromosome segregation.

Authors:  Brenda A Perez-Cheeks; Chong Lee; Ryo Hayama; Kenneth J Marians
Journal:  Mol Microbiol       Date:  2012-10-16       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.